Reported 23 days ago
Morgan Stanley has reiterated a Buy rating for LifeStance Health Group, Inc. (LFST), maintaining a price target of $10. The firm sees potential for the company to capitalize on increasing demand for outpatient mental health services, driven by a reduction in stigma and insurance coverage shifts. LifeStance's hybrid care model, combining in-person and virtual services, is expected to support growth, with management targeting margin expansion to 15%-20% by 2025. Despite recognizing LFST's potential, the analyst suggests that some AI stocks may offer better investment opportunities.
Source: YAHOO